2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1194

Support for Community-Based Programs for Managing Hip and Knee Osteoarthritis: Results of a Public Survey
Abstract Number: 1195

Rheumatology Nurse Advice Line in Singapore Tertiary Hospital – Pilot Study
Abstract Number: 1196

Patient Education in Spondyloarthritis Should be Guiding, Reliable and Available and Presented in Varied Formats
Abstract Number: 1197

Two Strategies for Recruiting Rural Faith-Based Organizations for a Fall-Prevention Exercise Intervention in a Population with High Rates of Arthritis
Abstract Number: 1198

Design and Implementation of a Patient-Centered Navigator Program to Improve Adherence to Disease-Modifying Antirheumatic Drugs
Abstract Number: 1199

The Charla De Lupus (Lupus Chat)® Program: An Evaluation of a Lupus Support Program for Teens, Young Adults and Parents
Abstract Number: 1200

Use of Focus Groups and Patient Partners to Revise an Internet Self-Management Program
Abstract Number: 1201

A Short Training on Solution Focused Approach May be Helpful in Providing Psychological Support Skills to Nurses Involved in Rheumatoid Arthritis
Abstract Number: 1202

Knowledge and Perception of Cardiovascular Disease Risk in Patients with Psoriatic Disease
Abstract Number: 1203

Patient Satisfaction and Outcomes of a NOVEL Ankylosing Spondylitis Education and Self-Management Project
Abstract Number: 1204

Measuring the Effectiveness of Patient Education of Patients Receiving Injectable Biologic Medications
Abstract Number: 1205

The Spectrum of Early RA Practice Across the Globe: Results from a Multinational Cross Sectional Survey
Abstract Number: 1206

Presence of ACPA in a Large (>40.000) Population Based Cohort from the Netherlands
Abstract Number: 1207

Predictive Utility of Anti- Citrullinated Peptide Antibodies and Rheumatoid Factor – a Retrospective Dataanalysis
Abstract Number: 1208

How Well Do Acpas Discriminate and Predict RA in the General Population – a Study Based on 12,590 Population-Representative Swedish Twins

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].